NSE: LUPIN · 8 October 2026 · Pre-market update
- Lupin Limited has launched Formoflo-G® MDI in India, becoming the world's first fixed-dose triple combination metered-dose inhaler for chronic obstructive pulmonary disease management. The rollout places the company's respiratory portfolio in focus as markets open following the previous trading day's close.
- Following approval from the Drug Controller General of India, Lupin introduced Formoflo-G® MDI for the long-term treatment of moderate to severe chronic obstructive pulmonary disease. The product combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate as a twice-daily, single-strength fixed dose targeting over 55 million COPD patients in India.
- Trading volume was 1.63 times the 20-day average daily volume.
LUPIN Company News Before Market Open
Lupin Limited has launched Formoflo-G® MDI in India, becoming the world's first fixed-dose triple combination metered-dose inhaler for chronic obstructive pulmonary disease management. The rollout places the company's respiratory portfolio in focus as markets open following the previous trading day's close.
The launch of Formoflo-G® MDI expands Lupin's respiratory portfolio in a key therapeutic category where the company holds a strong #2 market rank in India. The product addresses a major medical need for the estimated 55 million COPD patients living in India. Technical context shows the stock closed at ₹2029.3 on October 6, 2026, down 1.59% over the prior 5 trading days, keeping investor focus on fundamental catalysts.
10.66 lakh shares traded on 6 October 2026. This compares with a 20-day average daily volume of 6.54 lakh shares (1.63 times). The five-day average daily volume was 7.91 lakh shares.
The launch of Formoflo-G® MDI expands Lupin's respiratory portfolio in a key therapeutic category where the company holds a strong #2 market rank in India. The product addresses a major medical need for the estimated 55 million COPD patients living in India. Technical context shows the stock closed at ₹2029.3 on October 6, 2026, down 1.59% over the prior 5 trading days, keeping investor focus on fundamental catalysts.
Latest Company Developments
Following approval from the Drug Controller General of India, Lupin introduced Formoflo-G® MDI for the long-term treatment of moderate to severe chronic obstructive pulmonary disease. The product combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate as a twice-daily, single-strength fixed dose targeting over 55 million COPD patients in India.
The product launch reinforces Lupin's market position as the #2 player in India's respiratory therapy segment by expanding its specialized product offerings.
a press release dated October 06, 2026, titled "Lupin Launches Formoflo-G® MDI, World s First Fixed-dose Triple Combination Drug for COPD Management".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.84% on 30 June 2026. This compares with 16.93% on 31 March 2026, a change of -2.09 percentage points.
The filing reported 39 MF/UTI holders.
What to Watch Next
- Market reaction and trading volumes in Lupin shares following the open of the Indian cash market.
- Analyst commentary regarding the revenue potential and market adoption of Formoflo-G® MDI in India.
- Price action relative to the 20-day moving average close of ₹2076.63 and the prior session's trading range between ₹2003.0 and ₹2031.4.
Other Dated Coverage
- LUPIN Share Price Today: Why LUPIN Is Falling 0.81% | 7 October 2026 — 7 October 2026
- Why Lupin Shares Are Rising 0.91% Today With Sector Tailwinds | 6 October 2026 — 6 October 2026
More LUPIN news and dated analysis →
Frequently Asked Questions
What is the latest LUPIN company news?
Following approval from the Drug Controller General of India, Lupin introduced Formoflo-G® MDI for the long-term treatment of moderate to severe chronic obstructive pulmonary disease. The product combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate as a twice-daily, single-strength fixed dose targeting over 55 million COPD patients in India.
How strong was LUPIN’s trading volume?
10.66 lakh shares traded, 1.63 times the 20-day average daily volume. The price and volume data are dated 6 October 2026.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.